HUMAN is a EU-funded research project that started in October 2013. It aims to study the function of genetic risk variant associated to metabolic diseases with the use of mouse models with humanised liver and pancreas.
The HUMAN consortium associates a core of outstanding basic research institutions to leading European biotech SMEs taking advantage of both academic and SME partners who have the ad hoc facilities. The main goal of HUMAN is to offer European research and industries exclusive tools to tackle the challenge of functional validation of metabolic disease-associated genetic variants by offering: i) innovative and robust humanised animal and cellular models; ii) a portfolio of new and validated therapeutic targets for better understanding of metabolic diseases and healthy aging. HUMAN will generate iPSCs biobanks and comprehensively manage all associated information, including clinical and metabolic profiles of the donors, the phenotypes of iPSCs and of the different humanised mice, using state of the art technologies (proteomics, metabolomics, epigenomics, transcriptomics, glycomics). In sum, the HUMAN consortium is uniquely situated to drive innovation towards a better knowledge of the genetic basis of major human metabolic diseases, thereby contributing to the understanding of healthier aging of European citizens.
The research consortium is coordinated by Prof Knut R. Steffensen at the Karolinska Institute, University of Stockholm, Sweden. CRM researcher Dr David Hay is one of the partners in this project.